Whitehawk CEO sells shares to cover tax withholding
Whitehawk Therapeutics director and CEO David James Lennon sold shares to cover taxes tied to equity vesting.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Whitehawk Therapeutics director and CEO David James Lennon sold shares to cover taxes tied to equity vesting. Over April 6–8, 2026, he executed broker-assisted sales totaling 260,427 shares of Common Stock at prices around $3.40–$3.51 per share.
According to a footnote, these transactions were made solely to satisfy his tax withholding obligations in connection with the vesting of restricted stock units, rather than discretionary open-market sales. After these dispositions, he directly holds 533,122 Common Stock shares.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 63,945 | $3.40 | $217K |
| Sale | Common Stock | 94,087 | $3.43 | $323K |
| Sale | Common Stock | 102,395 | $3.51 | $359K |
Footnotes (1)
- F1. Represents a broker-assisted sale to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units.
Key Figures
Key Terms
broker-assisted sale financial
tax withholding obligations financial
restricted stock units financial
Common Stock financial
open-market sale financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Whitehawk Therapeutics (WHWK) CEO David James Lennon report in this Form 4?
Were the Whitehawk Therapeutics (WHWK) CEO’s Form 4 transactions open-market sales?
AI-generated analysis. How Rhea-AI works. Not financial advice.